Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Operating expenses:
Research and development	$ 21,192	$ 21,991	$ 75,111	$ 63,400
General and administrative	11,477	9,667	31,383	24,755
Total operating expenses	32,669	31,658	106,494	88,155
Loss from operations	(32,669)	(31,658)	(106,494)	(88,155)
Other income:
Other income and interest income	1,363	(197)	2,260	(53)
Net loss and net loss attributable to common stockholders	$ (31,306)	$ (31,855)	$ (104,234)	$ (88,208)
Net loss per share attributable to common stockholders, basic	$ (0.53)	$ (0.56)	$ (1.81)	$ (1.57)
Net loss per share attributable to common stockholders, diluted	$ (0.53)	$ (0.56)	$ (1.81)	$ (1.57)
Weighted average common shares outstanding, basic	58,872,334	56,629,193	57,679,635	56,108,492
Weighted average common shares outstanding, diluted	58,872,334	56,629,193	57,679,635	56,108,492
Comprehensive loss:
Net loss	$ (31,306)	$ (31,855)	$ (104,234)	$ (88,208)
Other comprehensive loss:
Unrealized losses on marketable securities	37	(3)	(302)	(8)
Comprehensive loss	$ (31,269)	$ (31,858)	$ (104,536)	$ (88,216)